W. R. Grace & Co. (Grace), a Standard Industries company and a global leader in specialty chemicals and solutions, has entered into a strategic, multi-year collaboration with Molecule.one, a global pioneer in chemical artificial intelligence and high-throughput chemistry. Molecule.one is also the winner of the Standard Industries Chemical Innovation Challenge. Through this agreement, the two companies will discover and deploy new, scalable approaches for manufacturing chemical compounds.
Phase One Focus: Peptide Building Block Synthesis
In the first phase, Grace and Molecule.one will accelerate the synthesis of selected peptide building blocks using Molecule.one’s MARIA™ AI and high-throughput experimentation platform. Together, the partners aim to address a critical supply chain bottleneck affecting peptide components—key inputs for manufacturing advanced therapeutics, including the rapidly expanding class of GLP-1 drugs used to treat weight loss and diabetes.
As demand for metabolic-disease peptides continues to rise, the global market is projected to more than double by 2030, exceeding $100 billion. Consequently, the collaboration responds to an urgent industry need for faster, more efficient scaling and production of peptide materials.
Leveraging Complementary Expertise
By combining Grace’s deep expertise in fine chemicals with Molecule.one’s award-winning AI and automation capabilities, the partnership seeks to transform how pharmaceutical compounds move from development to large-scale manufacturing. Importantly, the collaboration will also strengthen Grace’s fine chemicals manufacturing capabilities across its U.S. sites.
Brenda Kelly, President, Materials Technologies at Grace, noted that the partnership will significantly accelerate the production of complex peptide building blocks. She emphasized that shorter development timelines will help pharmaceutical manufacturers bring innovative therapies to patients more quickly.
AI-Powered Discovery and Scalable Manufacturing
Following Grace’s successful validation of the MARIA™ platform, both companies identified strong strategic alignment. Working closely with Grace scientists, Molecule.one will deploy its AI-driven system to optimize existing processes and uncover entirely new, scalable synthesis routes—starting with complex peptide building blocks.
According to Piotr Byrski, Co-founder and CEO of Molecule.one, this collaboration marks the first deployment of an AI-driven discovery and synthesis platform designed to support large-scale chemical manufacturing, from early-stage scale-up through full commercial production.
Accelerating Development Through Automation
With MARIA™ conducting advanced AI analysis and autonomously executing thousands of miniaturized reactions, Grace can rapidly identify and prioritize efficient production pathways. Moreover, the integration of computational chemistry with high-throughput experimentation ensures faster development cycles and reliable, reproducible results. As a result, pharmaceutical customers gain a significant advantage over conventional peptide synthesis methods, which often prove complex, inefficient, and difficult to scale.
Recognition Through the Chemical Innovation Challenge
The collaboration builds on Molecule.one’s recognition as the winner of the Standard Industries Chemical Innovation Challenge, a global initiative designed to accelerate innovation in chemical retrosynthesis using AI. As per company press release, selected from more than 30 competing teams, Molecule.one received the $1 million award in recognition of its advanced MARIA™ platform and its potential to reshape chemical manufacturing.
